161 related articles for article (PubMed ID: 36029387)
41. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a.
Youness RA; Hafez HM; Khallaf E; Assal RA; Abdel Motaal A; Gad MZ
J Cell Physiol; 2019 Nov; 234(11):20286-20297. PubMed ID: 30968427
[TBL] [Abstract][Full Text] [Related]
42. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
43. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
44. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
45. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
[TBL] [Abstract][Full Text] [Related]
46. Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer.
Chen R; Guo S; Yang C; Sun L; Zong B; Li K; Liu L; Tu G; Liu M; Liu S
Int J Oncol; 2020 Apr; 56(4):932-944. PubMed ID: 32319562
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
[TBL] [Abstract][Full Text] [Related]
48. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
49. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
50. The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population.
Lubanska D; Porter LA
Oncoscience; 2014; 1(5):336-48. PubMed ID: 25594028
[TBL] [Abstract][Full Text] [Related]
51. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Tarasewicz E; Rivas L; Hamdan R; Dokic D; Parimi V; Bernabe BP; Thomas A; Shea LD; Jeruss JS
Cell Cycle; 2014; 13(20):3191-201. PubMed ID: 25485498
[TBL] [Abstract][Full Text] [Related]
54. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
55. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
[TBL] [Abstract][Full Text] [Related]
56. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
57. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
58. ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.
Manna S; Bostner J; Sun Y; Miller LD; Alayev A; Schwartz NS; Lager E; Fornander T; Nordenskjöld B; Yu JJ; Stål O; Holz MK
Clin Cancer Res; 2016 Mar; 22(6):1421-31. PubMed ID: 26542058
[TBL] [Abstract][Full Text] [Related]
59. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
[TBL] [Abstract][Full Text] [Related]
60. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]